Medpace Holdings Inc (MEDP)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $18.29B
Last updated: Nov 17, 2026 at 11:06 AM ET
Medpace Holdings Inc (MEDP) Financials: Revenue, Profit and Cash Flow
Medpace Holdings reported revenue of $2.53B for the fiscal year ended Dec 31, 2025, up 20.0% from the year before. That year, net income was $451.12M with a net margin of 17.8%, operating cash flow was $713.22M and free cash flow was $681.87M. The quarter ended Sep 30, 2026 had revenue of $716.00M and net income of $137.46M.
Revenue and Margins
The operating margin was 21.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $421.58M, a compound annual rate of 22.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.53B | +20.0% | 100.0% | 21.1% | 17.8% |
| Dec 2024 | $2.11B | +11.8% | 100.0% | 21.2% | 19.2% |
| Dec 2023 | $1.89B | +29.2% | 100.0% | 17.9% | 15.0% |
| Dec 2022 | $1.46B | +27.8% | 100.0% | 19.1% | 16.8% |
| Dec 2021 | $1.14B | +23.4% | 100.0% | 17.4% | 15.9% |
| Dec 2020 | $925.92M | +7.5% | 100.0% | 18.0% | 15.7% |
| Dec 2019 | $860.97M | +22.2% | 100.0% | 14.8% | 11.7% |
| Dec 2018 | $704.59M | +61.5% | 30.6% | 14.3% | 10.4% |
| Dec 2017 | $436.15M | +3.5% | 51.4% | 14.9% | 9.0% |
| Dec 2016 | $421.58M | N/A | 87.9% | 12.5% | 3.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 11.6% from the year before. In the quarter ended Sep 2026, net income rose 23.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B | $925.92M | $860.97M | $704.59M | $436.15M | $421.58M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $489.06M | $211.77M | $50.96M |
| Gross profit | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B | $925.92M | $860.97M | $215.53M | $224.38M | $370.62M |
| Operating income | $534.93M | $446.87M | $336.82M | $278.70M | $198.62M | $167.04M | $127.26M | $101.05M | $64.86M | $52.49M |
| Net income | $451.12M | $404.39M | $282.81M | $245.37M | $181.85M | $145.38M | $100.44M | $73.19M | $39.12M | $13.43M |
| EBITDA | $557.72M | $480.18M | $362.50M | $308.11M | $223.08M | $187.05M | $149.74M | $133.81M | $102.86M | $112.76M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $716.00M | $707.33M | $706.60M | $708.45M | $659.90M | $603.31M | $558.57M | $536.59M | $533.32M | $528.10M | $511.04M | $498.40M |
| Gross profit | $716.00M | $707.33M | $706.60M | $708.45M | $659.90M | $603.31M | $558.57M | $536.59M | $533.32M | $528.10M | $511.04M | $498.40M |
| Operating income | $165.54M | $146.82M | $141.50M | $153.27M | $141.81M | $126.33M | $113.52M | $125.38M | $112.27M | $105.15M | $104.07M | $87.32M |
| Net income | $137.46M | $121.36M | $123.87M | $135.13M | $111.14M | $90.26M | $114.59M | $117.02M | $96.43M | $88.35M | $102.59M | $78.30M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $23.21M by $473.84M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.98B | $2.10B | $1.66B | $1.35B | $1.66B | $1.39B | $1.14B | $1.00B | $950.72M | $979.11M |
| Current assets | $989.62M | $1.03B | $593.83M | $333.96M | $690.91M | $473.65M | $317.03M | $177.74M | $129.97M | $133.25M |
| Cash and equivalents | $497.05M | $669.44M | $245.45M | $28.27M | $461.30M | $277.77M | $131.92M | $0 | $26.48M | $37.10M |
| Total liabilities | $1.52B | $1.28B | $1.10B | $966.11M | $707.01M | $584.90M | $416.79M | $405.92M | $447.19M | $368.39M |
| Short-term debt | $23.21M | $23.29M | $292.96M | $50.00M | $159.29M | $134.37M | $109.25M | $87.49M | $16.50M | $12.38M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $79.72M | $205.11M | $151.27M |
| Shareholder equity | $459.07M | $825.54M | $558.95M | $386.39M | $952.93M | $805.78M | $726.28M | $598.86M | $503.53M | $610.71M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.30B | $2.06B | $2.13B | $1.98B | $1.75B | $1.57B | $1.90B | $2.10B | $2.08B | $1.92B | $1.80B | $1.66B |
| Total liabilities | $1.72B | $1.62B | $1.53B | $1.52B | $1.46B | $1.40B | $1.30B | $1.28B | $1.20B | $1.16B | $1.12B | $1.10B |
| Cash and equivalents | $705.32M | $502.69M | $652.68M | $497.05M | $285.35M | $46.33M | $441.44M | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M |
| Shareholder equity | $584.94M | $433.86M | $598.31M | $459.07M | $293.64M | $172.35M | $593.61M | $825.54M | $881.44M | $763.60M | $671.54M | $558.95M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 95.6% of operating cash flow. Share repurchases came to 134.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $713.22M | $608.82M | $433.37M | $388.05M | $263.33M | $258.68M | $201.87M | $156.58M | $97.39M | $91.73M |
| Capital expenditures | $31.36M | $36.55M | $36.65M | $36.88M | $28.27M | $31.34M | $17.91M | $16.02M | $11.72M | $13.54M |
| Free cash flow | $681.87M | $572.27M | $396.73M | $351.17M | $235.06M | $227.34M | $183.96M | $140.56M | $85.66M | $78.19M |
| Dividends paid | N/A | N/A | $11.38M | $22.07M | N/A | N/A | N/A | N/A | $0 | $0 |
| Share repurchases | $917.39M | $169.87M | $144.02M | $847.85M | $62.10M | $98.27M | $0 | $0 | $155.58M | $2.72M |
| Investing cash flow | -$31.14M | -$28.31M | -$34.63M | -$38.74M | -$31.36M | -$31.21M | -$19.14M | -$16.97M | -$12.24M | -$13.42M |
| Financing cash flow | -$860.39M | -$154.01M | -$182.64M | -$775.77M | -$44.45M | -$82.28M | -$73.92M | -$141.58M | -$97.83M | -$58.01M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $216.60M | $162.01M | $151.79M | $192.65M | $246.21M | $148.53M | $125.84M | $190.67M | $149.07M | $116.40M | $152.68M | $156.40M |
| Capital expenditures | $20.16M | $23.91M | $6.81M | $4.54M | $10.71M | $6.11M | $9.99M | $7.64M | $10.54M | $12.87M | $5.50M | $9.99M |
| Free cash flow | $196.44M | $138.10M | $144.97M | $188.12M | $235.50M | $142.41M | $115.84M | $183.02M | $138.54M | $103.53M | $147.18M | $146.41M |
Frequently Asked Questions About MEDP
What is Medpace Holdings' annual revenue?
Medpace Holdings reported revenue of $2.53B for the fiscal year ended Dec 31, 2025.
How fast is Medpace Holdings' revenue growing?
Revenue was up 20.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.1%.
Is Medpace Holdings profitable?
Yes. Medpace Holdings reported net income of $451.12M for the fiscal year ended Dec 31, 2025, with a net margin of 17.8%.
How much free cash flow does MEDP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $713.22M minus capital expenditures of $31.36M produced free cash flow of $681.87M.
How much debt does Medpace Holdings have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $23.21M and cash and equivalents of $497.05M.
MEDP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors